Perjeta 420 MG/14 ML vial 14ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQWL4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,906
Award facts
- Contract value 100% obligated
- $4,905.81 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $4,905.81 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order, issued on January 16, 2026, with an ultimate completion date of February 9, 2026, operates under a firm fixed-price arrangement with no set-aside designation. This award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations.
DMS Pharmaceutical Group's PPV-G GEN V contract, designated as SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 through December 31, 2036, positioning the company as one of multiple regional prime vendor contractors. The broader contract authorizes DLA to issue delivery orders for comprehensive pharmaceutical products including branded and generic prescription medications, biologics, and medical consumables to support military healthcare facilities worldwide. Through this vehicle, DMS Pharmaceutical Group has demonstrated substantial federal contracting capability across diverse therapeutic categories, with the current delivery order for Perjeta—an oncology treatment—exemplifying the company's role as a critical supplier within the Department of Defense's global pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FQWL4?
SPE2DR26FQWL4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 16, 2026.
How much is contract SPE2DR26FQWL4 worth?
The government has obligated $4,906 on SPE2DR26FQWL4.
Is contract SPE2DR26FQWL4 an order under another contract?
Yes. SPE2DR26FQWL4 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWL4 competed?
The extent of competition for SPE2DR26FQWL4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award